vs

Side-by-side financial comparison of AMC Networks Inc. (AMCX) and Astrana Health, Inc. (ASTH). Click either name above to swap in a different company.

Astrana Health, Inc. is the larger business by last-quarter revenue ($950.5M vs $594.8M, roughly 1.6× AMC Networks Inc.). Astrana Health, Inc. runs the higher net margin — 0.7% vs -9.3%, a 10.0% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs -0.8%). AMC Networks Inc. produced more free cash flow last quarter ($40.4M vs $-6.0M). Over the past eight quarters, Astrana Health, Inc.'s revenue compounded faster (53.3% CAGR vs -0.1%).

AMC Networks Inc. is an American independent mass media and entertainment corporation headquartered in 11 Penn Plaza, New York City. The company owns and operates the eponymous cable channel, BBC America, IFC, Sundance TV, and We TV. It also owns the art house movie theater IFC Center in New York City; the independent film companies Independent Film Company and RLJE Films, the anime licensor Sentai Filmworks, the premium subscription streaming services AMC+, IFC Films Unlimited, Acorn TV, All...

Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.

AMCX vs ASTH — Head-to-Head

Bigger by revenue
ASTH
ASTH
1.6× larger
ASTH
$950.5M
$594.8M
AMCX
Growing faster (revenue YoY)
ASTH
ASTH
+43.6% gap
ASTH
42.9%
-0.8%
AMCX
Higher net margin
ASTH
ASTH
10.0% more per $
ASTH
0.7%
-9.3%
AMCX
More free cash flow
AMCX
AMCX
$46.4M more FCF
AMCX
$40.4M
$-6.0M
ASTH
Faster 2-yr revenue CAGR
ASTH
ASTH
Annualised
ASTH
53.3%
-0.1%
AMCX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AMCX
AMCX
ASTH
ASTH
Revenue
$594.8M
$950.5M
Net Profit
$-55.5M
$6.6M
Gross Margin
49.7%
Operating Margin
-8.6%
1.9%
Net Margin
-9.3%
0.7%
Revenue YoY
-0.8%
42.9%
Net Profit YoY
80.5%
184.4%
EPS (diluted)
$-0.97
$0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMCX
AMCX
ASTH
ASTH
Q4 25
$594.8M
$950.5M
Q3 25
$561.7M
$956.0M
Q2 25
$600.0M
$654.8M
Q1 25
$555.2M
$620.4M
Q4 24
$599.3M
$665.2M
Q3 24
$599.6M
$478.7M
Q2 24
$625.9M
$486.3M
Q1 24
$596.5M
$404.4M
Net Profit
AMCX
AMCX
ASTH
ASTH
Q4 25
$-55.5M
$6.6M
Q3 25
$76.5M
$373.0K
Q2 25
$50.3M
$9.4M
Q1 25
$18.0M
$6.7M
Q4 24
$-284.5M
$-7.8M
Q3 24
$41.4M
$16.1M
Q2 24
$-29.2M
$19.2M
Q1 24
$45.8M
$14.8M
Gross Margin
AMCX
AMCX
ASTH
ASTH
Q4 25
49.7%
Q3 25
48.2%
Q2 25
52.7%
Q1 25
51.8%
Q4 24
51.2%
Q3 24
52.0%
Q2 24
55.2%
Q1 24
54.5%
Operating Margin
AMCX
AMCX
ASTH
ASTH
Q4 25
-8.6%
1.9%
Q3 25
9.9%
2.0%
Q2 25
10.7%
3.1%
Q1 25
11.6%
3.3%
Q4 24
-42.4%
0.1%
Q3 24
15.6%
5.9%
Q2 24
1.7%
6.2%
Q1 24
18.5%
7.5%
Net Margin
AMCX
AMCX
ASTH
ASTH
Q4 25
-9.3%
0.7%
Q3 25
13.6%
0.0%
Q2 25
8.4%
1.4%
Q1 25
3.3%
1.1%
Q4 24
-47.5%
-1.2%
Q3 24
6.9%
3.4%
Q2 24
-4.7%
3.9%
Q1 24
7.7%
3.7%
EPS (diluted)
AMCX
AMCX
ASTH
ASTH
Q4 25
$-0.97
$0.12
Q3 25
$1.38
$0.01
Q2 25
$0.91
$0.19
Q1 25
$0.34
$0.14
Q4 24
$-6.23
$-0.14
Q3 24
$0.76
$0.33
Q2 24
$-0.66
$0.40
Q1 24
$1.03
$0.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMCX
AMCX
ASTH
ASTH
Cash + ST InvestmentsLiquidity on hand
$502.4M
$429.5M
Total DebtLower is stronger
$1.8B
Stockholders' EquityBook value
$981.9M
$779.3M
Total Assets
$3.9B
$2.2B
Debt / EquityLower = less leverage
1.78×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMCX
AMCX
ASTH
ASTH
Q4 25
$502.4M
$429.5M
Q3 25
$716.8M
$463.4M
Q2 25
$866.4M
$342.1M
Q1 25
$870.2M
$260.9M
Q4 24
$784.6M
$290.8M
Q3 24
$816.4M
$350.3M
Q2 24
$802.6M
$327.7M
Q1 24
$690.5M
$337.3M
Total Debt
AMCX
AMCX
ASTH
ASTH
Q4 25
$1.8B
Q3 25
$1.9B
Q2 25
$2.2B
Q1 25
$2.3B
Q4 24
$2.3B
Q3 24
$2.3B
Q2 24
$2.4B
Q1 24
$2.3B
Stockholders' Equity
AMCX
AMCX
ASTH
ASTH
Q4 25
$981.9M
$779.3M
Q3 25
$1.1B
$775.5M
Q2 25
$971.7M
$765.5M
Q1 25
$888.8M
$745.4M
Q4 24
$855.6M
$712.7M
Q3 24
$1.1B
$704.6M
Q2 24
$1.1B
$678.9M
Q1 24
$1.1B
$653.5M
Total Assets
AMCX
AMCX
ASTH
ASTH
Q4 25
$3.9B
$2.2B
Q3 25
$4.2B
$2.2B
Q2 25
$4.4B
$1.4B
Q1 25
$4.3B
$1.3B
Q4 24
$4.4B
$1.4B
Q3 24
$4.8B
$1.3B
Q2 24
$4.9B
$1.3B
Q1 24
$4.9B
$1.2B
Debt / Equity
AMCX
AMCX
ASTH
ASTH
Q4 25
1.78×
Q3 25
1.82×
Q2 25
2.27×
Q1 25
2.62×
Q4 24
2.73×
Q3 24
2.10×
Q2 24
2.26×
Q1 24
2.17×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMCX
AMCX
ASTH
ASTH
Operating Cash FlowLast quarter
$49.2M
$-2.9M
Free Cash FlowOCF − Capex
$40.4M
$-6.0M
FCF MarginFCF / Revenue
6.8%
-0.6%
Capex IntensityCapex / Revenue
1.5%
0.3%
Cash ConversionOCF / Net Profit
-0.44×
TTM Free Cash FlowTrailing 4 quarters
$272.4M
$104.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMCX
AMCX
ASTH
ASTH
Q4 25
$49.2M
$-2.9M
Q3 25
$44.8M
$10.0M
Q2 25
$102.8M
$90.9M
Q1 25
$108.8M
$16.6M
Q4 24
$58.1M
$-10.9M
Q3 24
$62.2M
$34.0M
Q2 24
$104.4M
$23.2M
Q1 24
$150.9M
$6.0M
Free Cash Flow
AMCX
AMCX
ASTH
ASTH
Q4 25
$40.4M
$-6.0M
Q3 25
$42.0M
$7.4M
Q2 25
$95.7M
$89.5M
Q1 25
$94.2M
$13.6M
Q4 24
$37.6M
$-13.5M
Q3 24
$53.9M
$31.7M
Q2 24
$95.2M
$20.4M
Q1 24
$144.1M
$5.6M
FCF Margin
AMCX
AMCX
ASTH
ASTH
Q4 25
6.8%
-0.6%
Q3 25
7.5%
0.8%
Q2 25
16.0%
13.7%
Q1 25
17.0%
2.2%
Q4 24
6.3%
-2.0%
Q3 24
9.0%
6.6%
Q2 24
15.2%
4.2%
Q1 24
24.2%
1.4%
Capex Intensity
AMCX
AMCX
ASTH
ASTH
Q4 25
1.5%
0.3%
Q3 25
0.5%
0.3%
Q2 25
1.2%
0.2%
Q1 25
2.6%
0.5%
Q4 24
3.4%
0.4%
Q3 24
1.4%
0.5%
Q2 24
1.5%
0.6%
Q1 24
1.1%
0.1%
Cash Conversion
AMCX
AMCX
ASTH
ASTH
Q4 25
-0.44×
Q3 25
0.59×
26.69×
Q2 25
2.04×
9.65×
Q1 25
6.03×
2.48×
Q4 24
Q3 24
1.50×
2.11×
Q2 24
1.21×
Q1 24
3.29×
0.40×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMCX
AMCX

Subscription And Circulation$314.8M53%
Advertising$124.9M21%
Other$79.1M13%
License$74.8M13%
Related Party$1.2M0%

ASTH
ASTH

Medicare$542.4M57%
Commercial$99.1M10%
Care Delivery$92.1M10%
Care Enablement$78.9M8%
Other Third Parties$58.0M6%
Health Care Patient Service$39.8M4%
Health Care Other$25.5M3%
Other$12.1M1%
Management Service$10.3M1%

Related Comparisons